Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV)
NCT ID: NCT03525132
Last Updated: 2019-06-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
290 participants
INTERVENTIONAL
2015-09-18
2020-09-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There is several quantitative approaches to study eye blood flow which do not answer all these specifications. The laser doppler velocimetry allows movement speed measures but not vessel diameter. Optical coherence tomography doppler allows a simultaneous diameter and speed of travel (movement) measures, but presents a limited spatial resolution and thereby not easily reproducible vessel diameter measures.
The investigators propose development of a technique allowing a simultaneous diameter and velocity measure of these vessels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Validity of Retinal Blood Flow Measurements During Hyperoxia in Humans Using Fourier Domain Color Doppler Optical Coherence Tomography (CDOCT)
NCT00431600
Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects
NCT01746615
Multimodal Imaging of Retinal Vessels
NCT02717026
Non-invasive Measurement of Retinal Blood Flow Based on Vessel Analysis and Fourier Domain Optical Coherence Tomography in Patients With Hypertensive Retinopathy
NCT01753648
"Predicting Glaucoma Progression With Optical Coherence Tomography Structural and Angiographic Parameters".
NCT04646122
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The difficulty to measure blood flow in humans is connected with the necessity of using not invasive, reliable and reproducible techniques.
There is several quantitative approaches to study eye blood flow which do not answer all these specifications. The laser doppler velocimetry allows movement speed measures but not vessel diameter. Optical coherence tomography doppler allows a simultaneous diameter and speed of travel (movement) measures, but presents a limited spatial resolution and thereby not easily reproducible vessel diameter measures.
The investigators propose development of a technique allowing a simultaneous diameter and velocity measure of these vessels.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy subjects
120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
Laser Doppler Velocimetry + Optic Adaptative Camera
Fluxometry measure while subject is sitting in front of the optic adaptative camera
Glaucoma
60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
Laser Doppler Velocimetry + Optic Adaptative Camera
Fluxometry measure while subject is sitting in front of the optic adaptative camera
Retinal vein occlusion
80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
Laser Doppler Velocimetry + Optic Adaptative Camera
Fluxometry measure while subject is sitting in front of the optic adaptative camera
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laser Doppler Velocimetry + Optic Adaptative Camera
Fluxometry measure while subject is sitting in front of the optic adaptative camera
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person affiliated to social security
* Age between 18 and 80 years
* Capable of focusing a target without ocular micro stuttering
* For healthy subject : absence of ocular and systemic pathology and no medical treatment
* For subject with glaucoma : Primitive open-angle glaucoma unilateral or bilateral. Visual field must be considerate as compatible and reliable with campimetric impairment known in glaucoma.
* For subject wih retinal veinous occlusion : Retinal central vein occlusion or branch retinal vein occlusion medically confirmed with an eye fundus exam and fluorescein angiography.
* Subject mentioned in L1121-5 to L1121-8 article of French Health Code : pregnant women, women capable of child bearing without contraceptive measures, under-age subject, subject under juridic protection or not able to give informed consent, subject deprived of liberty
* Any systemic medication with action on intraocular pressure such as sympathomimetic and beta blocker
* Hypersensitivity to tropicamide or its derivatives or to any eye drops excipients
* Subject who do not want to take part to the study
* Subject participating to another clinical trial
* Subject who can't come back for follow up visits
* Subject with lenses and who can't stop wearing them for the study protocol
* Close or narrow anterior chamber angle
* For healthy subject : Ametropia \> 3 diopter, subject with non evolutive or evolutive ocular pathology
* For subject with glaucoma : Ametropia \> 3 diopter, secondary glaucoma, closed angle glaucoma, isolated intraocular hypertonia, eye surgery within 3 months before the beginning of the study, trabeculoplasty, filtration surgery, associated evolutive or non-evolutive ocular pathology
* For subject with retinal veinous occlusion : Ametropia \> 3, associated evolutive or non-evolutive ocular pathology, patient already treated with intravitreal injection with anti-VEGF or dexamethasone implant (no older than 4 months)
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Florent Aptel, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Grenoble
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Grenoble
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Florent APTEL, MD, PhD
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Evaluation du flux sanguin oculaire. In: Rapport SFO 2014 - Glaucome primitif à angle ouvert.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-A01353-44
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.